Guggenheim analyst Michael Schmidt raised the firm's price target on Monte Rosa Therapeutics to $35 from $30 and keeps a Buy rating on the shares, which the analyst is also elevating to a "top-pick" for the second half of the year. The wholly-owned pipeline program MRT-8102 in Phase 1 is a key value driver and multiple industry data readouts in the second half could serve as significant potential stock catalysts, as well as increase the company's potential strategic value, the analyst tells investors.
